Vericel Corp (VCEL) stock intrinsic value fair value estimate & owner earnings analysis

Vericel sells three products to hospitals and surgeons in the United States: MACI, a cartilage implant grown from the patient's own cells and used to repair knee defects; Epicel, a permanent skin replacement grown from the patient's own skin for severe burns; and NexoBrid, an enzyme treatment that removes burned tissue, licensed from MediWound for North America. Revenue grew from $54 million in 2016 to $276 million in 2025 (16.5% growth in 2025), and the first half of 2026 was up a further 26% to $146 million. MACI is the large majority of sales and is the only FDA-approved product of its kind in the United States. The company has no borrowings, an undrawn $150 million JPMorgan credit line, and about $227 million of cash and investments at June 30, 2026. How we measure the earnings. We start from the cash the business generated, remove swings in receivables and inventory, and deduct stock compensation in full, because issuing shares to employees is a real cost to owners - it ran at $38.8 million in 2025, 14% of sales, and is the single largest reason the business has earned so little for its size. We deduct ordinary lease payments as a real cost. We do not deduct the cost of building the new 126,000 square foot Burlington, Massachusetts plant ($20 million in 2023, $64 million in 2024, $27 million in 2025): that is expansion, not upkeep. Instead we charge the business the roughly 3% of sales it has historically spent to maintain its equipment, about $7 million in 2025. Landlord construction allowances that passed through operating cash flow in 2023 and 2024 were removed as part of the build-out. On this basis owner earnings were negative every year from 2016 to 2023 and turned positive only recently: about $13.5 million in 2024 and $24.7 million in 2025 ($0.47 a share). About $7 million a year of that is interest on the cash pile, which we count once as cash rather than also as earnings, so the operating business produced about $7.5 million in 2024 and $18 million in 2025. The starting point. The business before 2024 was too small to cover its sales force and stock compensation, so those years describe a different stage of the company. We start the cases from about $20-24 million of operating cash earnings for 2026, close to the 2025 level rather than a single good year, with the 2024-2025 record and the first-half 2026 revenue growth as support. Operating earnings grew far faster than that in 2025 (from $7.5 million to $18 million) because manufacturing costs are mostly fixed; every case assumes a much slower year one than that. What growth we credit and why. Vericel has grown revenue at about 20% a year for nine years and about 15% a year over the last four, through the 2020 shutdown, by steadily adding surgeons and raising price. We credit a slower, tapering version of that demonstrated record. We do not credit MACI Ankle (still in a clinical trial), any approval outside the United States, or any new product. Each extra dollar of sales has added 27-31 cents of operating cash in 2024-2025; we assume less, because running two plants (Cambridge and Burlington) adds cost. Base case: revenue grows 18% in 2026 (consistent with the first half), then slows steadily from 12% to 4% by 2035, reaching about $610 million, with operating cash earnings of about $79 million (13% of sales). MACI's patents run to 2039-2043 and its regulatory data exclusivity to December 2028, but the bigger protection is that growing a patient's own cells under FDA approval is hard to copy; we hold earnings flat to 2043 and fade them to zero by 2053 as patents lapse. The business is worth about $740 million; adding about $197 million of cash beyond what operations need (and subtracting a small finance lease) gives about $937 million, or $17.92 a share. Bear case: elective orthopedic surgery has fallen sharply before - in the 2020 shutdown Vericel's second-quarter revenue dropped 24%. The bear case puts a worse version of that into 2029: a 15% revenue fall in one year, from a shutdown, a production outage at the single licensed Cambridge plant before Burlington is qualified (the risk the company itself names first), or share loss to Smith & Nephew's Agili-C cartilage implant. Because costs are fixed, operating cash turns slightly negative for two years, then recovers only to low single-digit margins with growth of 1-3%, and earnings fade to zero by 2043. The business is worth only about $75 million; with no debt and about $197 million of surplus cash, the shares are worth about $5.19, most of it the cash. Bull case: the demonstrated surgeon and price growth continues more strongly, from 22% in 2026 tapering to 6% by 2035 (about $814 million of revenue), with each new sales dollar adding 28 cents of cash as in 2024-2025, and earning power held to 2045 before fading. The business is worth about $1.45 billion; with cash, about $31.52 a share. What could make this wrong. First, stock compensation: if it keeps growing in step with revenue, the operating leverage in all three cases shrinks. Second, the plant: until FDA qualifies Burlington, all US MACI and Epicel production depends on one Cambridge building. Third, competition from Agili-C, backed by Smith & Nephew's resources. On the other side, no debt and a large cash balance mean the company would survive any of these. Margin of safety price: $8.00. We are only moderately sure of the earnings level - the business has two positive years after eight negative ones. The worst plausible event, a long production outage before Burlington is qualified, would hurt badly, but with no debt and $227 million of cash the company would survive it; shareholders would not be wiped out. If we are wrong about stock compensation and about competition at the same time, the shares are worth roughly the cash plus a small business, around $5-6. The company pays no dividend, so the whole return has to come from the business growing into its value, and the price assumes a holding period of about five years. At $8.00, roughly $3.80 a share is covered by surplus cash, the remainder values an established, growing medical franchise at about 15 years' worth of its 2025 operating cash earnings, and if the business merely tracks its recent record the base case implies a value five years out well over twice that price. Our previous analysis used a different measure of earnings, so the earlier figures are not directly comparable; the business itself has improved, with higher 2025 earnings and 26% revenue growth in the first half of 2026.